Silo Pharma (NASDAQ: SILO), a developmental-stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, has announced a stock repurchase program. According to the company, its board of directors has approved the program, which will acquire up to $1 million of the company’s common stock. The announcement noted that the company could purchase common stock in a variety of ways, including in the open market and through privately negotiated transactions; all transactions will be in compliance with United States Securities and Exchange Commission rules and guidelines. The repurchase of stocks will depend on available liquidity, cash flows and market conditions and will also take into consideration corporate and regulatory limitations; the company observed that it is not committed to acquiring a specific amount of shares and that the repurchase program may be suspended or discontinued at any time. As of Nov. 10, 2022, the company had approximately 3,138,797 million shares of common stock outstanding. “The current capital market conditions allow us to capture additional value for all shareholders through this measured buyback program,” said Silo Pharma CEI Eric Weisblum in the press release. “Our board of directors and executive management team remain committed to delivering value to our shareholders.”
To view the full press release, visit https://ibn.fm/w08lE
About Silo Pharma Inc.
Silo Pharma is a developmental-stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research indications for people suffering from indications such as Alzheimer’s disease, PTSD and other rare neurological disorders. Silo’s mission is to identify assets to license and fund the research that the company believes will be transformative to the well-being of patients and the healthcare industry. For more information about the company, visit www.SiloPharma.com.
NOTE TO INVESTORS: The latest news and updates relating to SILO are available in the company’s newsroom at https://ibn.fm/SILO
About MissionIRNewsBreaks
MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
